WGS
GeneDx Holdings Corp.
Diagnostics & Research · Healthcare · United States
71.02
close · 2026-10-29
value
19
cheaper than peers19
quality
19
stronger fundamentals19
ranked against
Diagnostics & Research
value
quality
31 peers
Value inputs
| measure | company | vs peers |
| price to sales | 4.75× | 50 |
| price to book | 8.67× | 29 |
| forward P/E | 59.25× | 8 |
3 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 17.4% | 66 |
| debt to equity | 66.2% | 43 |
| operating margin | -25.6% | 18 |
| return on equity | -30.4% | 16 |
4 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $3.6M |
| employees | 1,300 |
| first trade | 2020-11-04 |
| next earnings | 2026-11-09 |
| fundamentals updated | 2026-08-04 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.73 | -1.94 | -7.23 | -53.79 |
| free cash flow | $14.3M | -$34.0M | -$185.9M | -$333.5M |
| net income | -$21.0M | -$52.3M | -$175.8M | -$549.0M |
| revenue | $427.5M | $305.4M | $202.6M | $234.7M |
| unusual items | -$1.2M | -$13.4M | -$9.2M | -$139.9M |